• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Science & Medicine / Cancer / HPV Testing for Patients with Atypical Squamous Cells Identifies Those at High Risk for Cancer

HPV Testing for Patients with Atypical Squamous Cells Identifies Those at High Risk for Cancer

January 17, 2011 By Norma Leave a Comment

By:  Barbara Boughton

02 November 2010

(San Francisco, California) — A new study from an inner-city hospital in Atlanta, Georgia, of 348 patients with a diagnosis of atypical squamous cells of undetermined significance (ASC-US) confirms that high-risk human papillomavirus (HPV) assay testing is essential for pinpointing patients with high-grade dysplasia who need follow-up treatment, according to research presented here at the American Society for Clinical Pathology (ASCP) 2010 Annual Meeting.

In the retrospective study, high-risk HPV testing was able to identify all patients with cervical intraepithelial neoplasia (CIN) 3 lesions and almost all patients (96%) with CIN 2 lesions, using the Hybrid Capture 2 (HC2) HPV assay for detecting cervical cancer precursor lesions on SurePath specimens.

“These are patients who don’t come in for regular testing and tend to present with pretty advanced disease. We wanted to evaluate patients with a diagnosis of ASC-US in this population to see the rate of high-risk HPV positivity,” said presenting researcher Beth Chastain, MD, from Emory University School of Medicine and Grady Memorial Hospital in Atlanta.

“If we can give these patients an HPV test during their initial visit, we can assess where they are at and get them treated more easily,” Dr. Chastain said. “It’s important not to let these patients fall through the cracks.”

From 2006 to 2008, data collected from SurePath Pap tests interpreted as ASC-US on high-risk HPV testing and histologic follow-up — such as cervical/cone biopsy, endocervical curettage, and hysterectomy — were analyzed.

At Grady Hospital, Dr. Chastain reported that the rate of ASC-US is 11.5%, which is twice the national average. Among patients with ASC-US, 63% were high-risk HPV-positive. In this subgroup, 54% had high-grade dysplasia, and the rate of severe dysplasia/carcinoma in situ was 10.4%. In contrast, no patients who tested high-risk HPV-negative had severe dysplasia/carcinoma on follow-up.

Of 220 high-risk HPV-positive samples, 60 patients (27.3%) had negative histology on follow-up, a finding that might be explained by regression or limited sampling, the researchers say. These conflicting results suggest a need for further follow-up of these patients, Dr. Chastain and colleagues conclude.

“The ALTS [ASC-US/LSIL Triage Study] showed unequivocally that you should do a clinically valid test for high-risk HPV types to distinguish patients in the ASC-US population who are at risk for CIN 3 and those who aren’t,” said Mark Stoler, MD, professor of pathology and gynecology and associate director of surgical pathology and cytopathology at the University of Virginia Health System in Richmond. Dr. Stoler is president of the ASCP.

Read the entire article here.

Related

Filed Under: Cancer, HPV Science Tagged With: cervical intraepithelial neoplasia, HPV, lesions, test

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Nikki from Massachusetts

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

Gardasil Vaccine, Injection of Death!: Dr. Sherri Tenpenny Reports

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in